Pasithea Therapeutics Corp.
General ticker "KTTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.8M (TTM average)
Pasithea Therapeutics Corp. does not follow the US Stock Market performance with the rate: -28.6%.
Estimated limits based on current volatility of 9.3%: low 0.50$, high 0.60$
Factors to consider:
- Earnings expected soon, date: 2026-11-12 bmo
- Total employees count: 5 as of 2025
- Top business risk factors: Limited operating history, History of losses, Dependence on lead candidate, Regulatory and compliance, Capital raising
- Current price 28.9% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.76$, 2.37$]
- 2026-12-31 to 2027-12-31 estimated range: [0.61$, 1.93$]
Financial Metrics affecting the KTTA estimates:
- Negative: with PPE of -0.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 91.67 > 81.82
- Positive: -0.07 < Investing cash flow per share per price, % of 0.13
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term KTTA quotes
Long-term KTTA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $15.98MM | $14.25MM | $20.86MM |
| Operating Income | $-15.98MM | $-14.25MM | $-20.86MM |
| Non-Operating Income | $0.47MM | $0.35MM | $0.43MM |
| R&D Expense | $8.10MM | $7.20MM | $7.98MM |
| Income(Loss) | $-15.51MM | $-13.90MM | $-20.43MM |
| Other Income(Loss) | $-0.45MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-15.96MM | $-13.90MM | $-20.43MM |
| Stockholders Equity | $23.40MM | $14.78MM | $55.22MM |
| Assets | $26.12MM | $16.06MM | $60.24MM |
| Operating Cash Flow | $-13.43MM | $-13.92MM | $-15.21MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $0.40MM | $0.00MM | $0.01MM |
| Financing Cash Flow | $-3.73MM | $4.52MM | $63.52MM |
| Earnings Per Share** | $-13.01 | $-12.69 | $-2.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.